PSParin Shah

Parin Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Parin Shah has a total of 250 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S1 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Supplemental Table 1: Assays performed and basic quality metrics of included samples.

  • Open Access

    Supplementary Table S3 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Supplemental Table 3: T-cell receptor sequences and clonality.

  • Open Access

    Data from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Purpose:Sarcoma encompasses a diverse group of cancers that are typically resistant to current therapies, including immune checkpoint blockade (ICB), and underlying mechanisms are poorly understood. The contexture of sarcomas limits generation of high-quality data using cutting-edge molecular profiling methods, such as single-cell RNA-sequencing, thus hampering progress in understanding these understudied cancers.Experimental Design:Here, we demonstrate feasibility of producing multimodal single-cell genomics and whole-genome sequencing data from frozen tissues, profiling 75,716 cell transcriptomes of five undifferentiated pleomorphic sarcoma and three intimal sarcoma samples, including paired specimens from two patients treated with ICB.Results:We find that genomic diversity decreases in patients with response to ICB, and, in unbiased analyses, identify cancer cell programs associated with therapy resistance. Although interactions of tumor-infiltrating T lymphocytes within the tumor ecosystem increase in ICB responders, clonal expansion of CD8+ T cells alone was insufficient to predict drug responses.Conclusions:This study provides a framework for studying rare tumors and identifies salient and treatment-associated cancer cell intrinsic and tumor microenvironmental features in sarcomas.

  • Open Access

    Supplementary Figure S1 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Violin plots and boxplots displaying the (a) genes detected per cell and (b) stress signature expression per cell and (c) mitochondrial fraction of reads in samples profiled from fresh or frozen tissue in this study and in indicated studies by Jerby et. al. (dijon) and Slyper et al. (green), respectively. The upper and lower edges of the boxplot display the 75th and 25th percentiles respectively. Blue violin plots are from scRNA-seq from fresh tissue, and red violin plots are from snRNA-seq on frozen tissue.

  • Open Access

    Supplementary Table S2 from Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Supplemental Table 2: Pathway enrichment analyses for indicated samples.

  • Open Access

    Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer

    by Casey R. Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L. E. Wang, Neha Shaikh, Parin Shah, Samuel S. Pan, Caroline J. Laplaca, Renu K. Virk, et al.

    Men with high-risk localized prostate cancer exhibit high rates of post-surgical recurrence. In these patients, androgen deprivation therapy (ADT) is immunomodulatory, however increased infiltration of regulatory T cells (Tregs) may limit the antitumor immune effects of ADT. We designed a neoadjuvant clinical trial to test whether BMS-986218 – a next-generation non-fucosylated anti-CTLA-4 antibody engineered for enhanced antibody-dependent cellular cytotoxicity or phagocytosis (ADCC/P) – depletes intratumoral Tregs and augments the response to ADT. In this single-center, two-arm, open-label study, 24 men with high-risk localized prostate cancer were randomized to receive a single dose of ADT with or without two pre-operative doses of BMS-986218 (anti-CTLA4-NF) prior to radical prostatectomy. Treatment was well tolerated and feasible in the neoadjuvant setting. A secondary clinical outcome was the rate of disease recurrence, which was lower than predicted in both arms. Mechanistically, anti-CTLA4-NF reduced ADT-induced Treg accumulation through engagement of CD16a/FCGR3A on tumor macrophages, and depth of Treg depletion was quantitatively associated with clinical outcome. Increased intratumoral dendritic cell (DC) frequencies also associated with lack of recurrence, and pre-clinical data suggest ADCC/P-competent anti-CTLA-4 antibodies elicit activation and expansion of tumor DCs. Patients receiving anti-CTLA4-NF also exhibited phenotypic signatures of enhanced antitumor T cell priming. In total, this study provides the first-in-human evidence of Treg depletion by glycoengineered antibodies targeting CTLA-4 in humans and their potential in combination with ADT in prostate cancer patients with high-risk of recurrence.


  • Open Access

    Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade

    by Karan Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms, Sinan Abuzaid, Viktoria Jakubikova, D. Zack Brodtman, Sminu Bose, Amit Dipak Amin, Patricia Ho, et al.

    Purpose: Sarcoma encompasses a diverse group of cancers that are typically resistant to current therapies, including immune checkpoint blockade (ICB), and underlying mechanisms are poorly understood. The contexture of sarcomas limits generation of high-quality data using cutting-edge molecular profiling methods, such as single-cell RNA-sequencing, thus hampering progress in understanding these understudied cancers. Experimental Design: Here, we demonstrate feasibility of producing multimodal single-cell genomics and whole-genome sequencing data from frozen tissues, profiling 75,716 cell transcriptomes of five undifferentiated pleomorphic sarcoma and three intimal sarcoma samples, including paired specimens from two patients treated with ICB. Results: We find that genomic diversity decreases in patients with response to ICB, and, in unbiased analyses, identify cancer cell programs associated with therapy resistance. Although interactions of tumor-infiltrating T lymphocytes within the tumor ecosystem increase in ICB responders, clonal expansion of CD8+ T cells alone was insufficient to predict drug responses. Conclusions: This study provides a framework for studying rare tumors and identifies salient and treatment-associated cancer cell intrinsic and tumor microenvironmental features in sarcomas.


  • Open Access

    Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

    by Jana Biermann, Yiping Wang, Linyue Fan, Patricia Ho, Amit D. Amin, Johannes C. Melms, Somnath Tagore, Kevin Hoffer-Hawlik, Parin Shah, Neha Shaikh, et al.

    Immune checkpoint blockade (ICB) targeting CTLA-4 or the PD1/PD-L1 axis have become a standard of care therapy for most patients with metastatic melanoma. However, for patients with resistance to front-line ICB, especially those with BRAFWT tumors who received combination therapy, subsequent therapeutic options remain limited. Thus, understanding how ICB alters the tumor ecosystem, and thereby may create new vulnerabilities, is key to understanding effective therapies for ICB-experienced patients. Here, enabled through innovations in biospecimen research, we performed multi-modal single-cell RNA, T-cell receptor and single-cell spatial transcriptomics, coupled with whole-genome sequencing (WGS) of 42 melanoma patient biopsies. This cohort includes 7 patients with paired before- and on-/post-treatment biopsies, and spanned treatment-naïve metastatic cutaneous melanoma patients (n=10), on-ICB (aPD-1, n=7; aCTLA-4, n=1; combination therapy, n=2; total, n=10), and post-ICB (aPD-1, n=10; aCTLA-4, n=5; combination therapy, n=6; L19IL2+L16TNF, n=1; total, n=22). This cohort further includes 6 rare samples of mucosal melanoma (oral, n=4; rectal, n=2). In total, we profiled >320,000 transcriptomes, including >240,000 malignant and ~80,000 non-malignant cells, and 14,714 matched TCRs. We used a series of novel analytical approaches, including KINOMO to mitigate biases introduced by differences in gene dosage, and novel artificial intelligence frameworks, to discover differentially expressed genes and gene programs associated with treatment exposures and treatment sites. Compared to untreated specimens, there is an increase in antigen presentation (Wilcoxon rank-sum test, P=0) and reduction in lineage expression (Wilcoxon rank-sum test, P=0) in ICB-experienced tumors. Furthermore, mucosal melanomas harbor unique gene regulatory networks characterized by expression of immune evasive programs (e.g. SOX4; MAST, P=0) and exhibit lower expression of oxidative phosphorylation (Wilcoxon rank-sum test, P=0). Together, these data indicate a high degree of cellular adaption and plasticity. Through integration of single-cell, spatial and WGS, we further identify cancer clones defined by their aneuploidy patterns that confer geographically restricted immune evasion with a distinctly cold tumor microenvironment (TME), despite global T cell activation and clonal expansion. This suggest significant intralesional heterogeneity with respect to response to ICB, which may be explained by cancer cell-intrinsic factors rather than insufficient T cell responses to ICB. This work provides initial insights into spatio-temporal changes induced by ICB in cancer cells and the TME in a relatively large patient cohort. Our results indicate that functional and spatial variability exists in these tumors and may provide avenues for novel therapeutic development in ICB-experienced patients. Citation Format: Jana Biermann, Yiping Wang, Linyue Fan, Patricia Ho, Amit D. Amin, Johannes C. Melms, Somnath Tagore, Kevin Hoffer-Hawlik, Parin Shah, Neha Shaikh, Priyanka Ramaradj, Mingxuan Zhang, Antoni Ribas, Caroline Robert, Elham Azizi, Benjamin Izar. Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 109.

  • Open Access

    Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies

    by Z. Johnson, E. Papakonstanti, A. Tsapara, A. Macqueen, P. Shah, L. Van der Veen, M. Lahn

    Inhibiting PI3Kδ preferentially targets regulatory T cells and myeloid derived suppressor cells, breaking tumour-induced immune tolerance and restoring anti-tumour immunity. Bioinformatics and protein expression studies have shown that PIK3CD / PI3Kδ is highly expressed in certain solid malignancies, and therefore inhibition of PI3Kδ may modulate tumour growth and development via intrinsic as well as immune driven effects. In vitro proliferation of primary human T cells demonstrated the selective effects of PI3Kδ inhibition on Treg cells. In vivo immune mediated effects of IOA-244 were tested using the CT26 mouse model. High PI3Kδ expressing MDA-MB-231 breast cancer cells, as well as a patient derived melanoma model with high PIK3CD profile were tested in T cell deficient hosts. IOA-244 is a novel, highly selective PI3Kδ inhibitor, with the unique property of being ATP non-competitive. IOA-244 showed a selective and concentration-dependent suppression of human Treg cell proliferation whilst leaving CD8+ T cell proliferation intact. In mouse models with a full immune system, IOA-244 inhibited tumour growth when combined with either anti-PD-1 or anti-PD-L1. Furthermore, the composition of the tumour infiltrating lymphocytes showed a marked decrease in the suppressor cell populations, i.e. Tregs and MDSCs. In nude mice we demonstrated that IOA-244 can effectively inhibit the growth of PI3Kδ-expressing breast cancer cells as a monotherapy. To support the clinical development of IOA-244 we demonstrate that patient derived melanoma cells with a high expression of PIK3CD are susceptible to treatment with IOA-244 in a mouse patient-derived xenograft model. Solid tumours with a high Treg:CD8 ratio and / or a high protein expression of PI3Kδ may be amenable to treatment with IOA-244. Based on these and other supporting data, IOA-244 has received clinical trial approval in two European countries and phase I clinical testing is expected to start by the end of 2020. iOnctura SA. iOnctura SA. Z. Johnson: Leadership role: iOnctura SA. L. Van der Veen: Leadership role: iOnctura SA. M. Lahn: Leadership role: iOnctura SA. All other authors have declared no conflicts of interest.


  • Open Access

    Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature

    by Jessica Roelands, Mathieu Garand, Emily Hinchcliff, Ying Ma, Parin Shah, Mohammed Toufiq, Mohamed Alfaki, Wouter Hendrickx, Sabri Boughorbel, Darawan Rinchai, et al.

    A potential role for the long-chain acyl-CoA synthetase family member 1 (ACSL1) in the immunobiology of sepsis was explored during a hands-on training workshop. Participants first assessed the robustness of the potential gap in biomedical knowledge identified via an initial screen of public transcriptome data and of the literature associated with ACSL1. Increase in ACSL1 transcript abundance during sepsis was confirmed in several independent datasets. Querying the ACSL1 literature also confirmed the absence of reports associating ACSL1 with sepsis. Inferences drawn from both the literature (via indirect associations) and public transcriptome data (via correlation) point to the likely participation of ACSL1 and ACSL4, another family member, in inflammasome activation in neutrophils during sepsis. Furthermore, available clinical data indicate that levels of ACSL1 and ACSL4 induction was significantly higher in fatal cases of sepsis. This denotes potential translational relevance and is consistent with involvement in pathways driving potentially deleterious systemic inflammation. Finally, while ACSL1 expression was induced in blood in vitro by a wide range of pathogen-derived factors as well as TNF, induction of ACSL4 appeared restricted to flagellated bacteria and pathogen-derived TLR5 agonists and IFNG. Taken together, this joint review of public literature and omics data records points to two members of the acyl-CoA synthetase family potentially playing a role in inflammasome activation in neutrophils. Translation relevance of these observations in the context of sepsis and other inflammatory conditions remain to be investigated.